C10X polymorphism in the CARD8 gene is associated with bacteraemia

Berhane Asfaw Idosa1, Berolla Sahdo1, Ermias Balcha1, Anne Kelly1, Bo Söderquist2,3, & Eva Särndahl1,3

1Department of Clinical Medicine, School of Health and Medical Sciences, Örebro University, SE-701 82, Örebro, Sweden
2Department of Laboratory Medicine, Clinical Microbiology, Örebro University Hospital, SE-701 85, Örebro, Sweden
3Faculty of Medicine and Health, Örebro University, SE-701 82, Örebro, Sweden

Abstract

The NLRP3 inflammasome is an intracellular multi-protein complex that triggers caspase-1 mediated maturation of interleukin-1β (IL-1β); one of the most potent mediators of inflammation and a major cytokine produced during severe infections, like sepsis. However, the excessive cytokine levels seem to stage for tissue injury and organ failure, and high levels of IL-1β correlates with severity and mortality of sepsis. Instead, recent data suggest caspase-1 to function as a guardian against severe infections. CARD8 has been implied to regulate the synthesis of IL-1β via interaction to caspase-1. In recent years, polymorphism of CARD8 (C10X) per se or in combination with NLRP3 (Q705K) has been implicated with increased risk of inflammation. The aim was to investigate the correlation of these polymorphisms with severe blood stream infection. Human DNA was extracted from blood culture bottles that were found to be positive for microbial growth (i.e. patients with bacteraemia). Polymorphisms Q705K in the NLRP3 gene and C10X in the CARD8 gene were genotyped using TaqMan genotyping assay. The results were compared to healthy controls and to samples from patients with negative cultures. The polymorphism C10X was significantly over-represented among patients with bacteraemia as compared to healthy controls, whereas patients with negative blood culture were not associated with a higher prevalence. No association was observed with polymorphism Q705K of NLRP3 in either group of patients. Patients carrying polymorphism C10X in the CARD8 gene are at increased risk of developing bacteraemia and severe inflammation.

Introduction

The innate immune system has evolved as a system that control microbial infections. Upon sensing the presence of pathogens, host innate immune cells initiate a broad spectrum of defence mechanisms that results in the development of inflammation and host resistance to infection. A key component of cytosolic surveillance is the NLRP3 inflammasome (reviewed in: [1]). By sensing a variety of microbial components, as well as endogenous and exogenous danger molecules, NLRP3 forms a multi-protein inflammasome complex that controls the activation of the proteolytic enzyme caspase-1. Caspase-1 in turn regulates the maturation of the proinflammatory cytokines: interleukin (IL)-1β and IL-18. IL-1β is one of the most potent mediators of inflammation, for example causing leukocytosis and fever [2]. IL-1β is also one of the important cytokines produced during severe infection, such as invasive infections. Despite this proinflammatory involvement, it is well documented that the innate immune system in septic patients is suppressed and unable to clear pathogens. The excessive cytokine levels seem rather to stage for tissue injury...
and organ failure [3], and high levels of IL-1β correlate with severity of disease and mortality [4]. Recent data indicate instead a role for caspase-1 in controlling severe infections [5–7]. CARD8 (also known as TUCAN/CARDINAL) has been found to be involved in NFκB-mediated suppression of the immune response and inflammatory activities [8]. A role in inflammasome-mediated processes has been proposed as CARD8 has been found to regulate IL-1β secretion [9] and cell death [10, 11], probably by a direct physical interaction to caspase-1.

Variations in genes encoding the NLRP3 inflammasome are associated with auto-inflammatory diseases, and Q705K in NLRP3 and C10X in CARD8 are two polymorphisms that, per se or combined, have been associated with increased risk and severity of chronic inflammation [12–19]. The Q705K polymorphism renders NLRP3 into a gain-of-function phenotype [20], which results in a lower threshold for activation, whereas the C10X polymorphism results in a truncated non-functional protein and thus the loss of CARD8-mediated inhibition of caspase-1 [11]; that is both polymorphisms create a more susceptible inflammasome, which could be detrimental if leading to an inappropriate immune response. Actually, this could display a higher incidence or severity of inflammation in the setting of severe infections. In the present study, severely ill patients with suspected bacteraemia were investigated to find out if genetic variations of the NLRP3 inflammasome influence susceptibility to develop blood stream infection. The polymorphism C10X in the CARD8 gene was found to be significantly over-represented among patients with bacteraemia as compared to healthy controls, whereas patients with negative blood culture were not associated with a higher prevalence.

Materials and Methods

Study subjects

Blood from a total of 100 positive and 100 negative blood culture bottles (BD BACTEC plus aerobic and anaerobic bottles; Becton, Dickinson and company, Franklin Lakes, NJ, USA) were collected consecutively during 2 months (January–February, 2012) by the accredited Department of Laboratory Medicine, Clinical Microbiology, Örebro University Hospital, Sweden. Each sample originated from a distinct patient. The infectious agents (bacterium and fungi) were isolated and identified according to routine laboratory procedures. For each distinct patient, four separate blood samples, two anaerobic and two aerobic, were cultured. If no indication of growth was obtained within 7 days, the samples were considered as negative. Coagulase-negative staphylococci (CoNS) were regarded as significant if growth were detected in two or more of the four separate blood culture bottles.

From the blood, human DNA was successfully extracted from 70 patients (60% male and 40% female; mean age: 69 (range: 0–99) years) with bacteraemia (positive) and from 76 patients (54% male and 46% female; mean age. 61 (range: 1–96) years) with no growth of microbes (negative), whereas human DNA was undetectable in the rest of the samples and these samples were thereby excluded from the study. One-thousand-three healthy individuals, previously analyzed [21], were used as controls (63% male, 37% female; mean age: 42 (range: 19–67) years). The variant allele frequencies of Q705K (rs35829419) in NLRP3 and C10X (rs2043211) in CARD8 genes in the control group were 7.2% and 32.9%, respectively [21], which is in agreement with previous studies [12, 17] and the National Center for Biotechnology Information (NCBI) reference assembly on European population. Both polymorphisms were found to be in Hardy–Weinberg equilibrium.

DNA extraction

DNA was isolated directly from blood culture bottles by pre-chemical lysis treatment and automated extraction method using Roche MagNA pure instrument (Roche Diagnostics GmbH, Mannheim, Germany) in accordance with the manufacturer’s instructions. 2 mL aliquots of broth from blood culture bottles were centrifuged at 140 g for 10 min and 200 µL supernatant was removed for further processing. Prior to MagNA pure compact, the specimens were treated with 10 µL of mutanolysin (Roche Diagnostic GmbH) and incubated at 37°C for 10 min. 180 µL of bacterial lysis buffer (Roche Diagnostic GmbH) and 20 µL proteinase K (Roche Diagnostic GmbH) were added to the specimens. After brief vortexing, specimens were incubated for 10 min at 65°C and subsequently, subjected to 95°C boiling for 10 min. Treated samples (400 µL) were transferred to the MagNA Pure Compact instrument for automated DNA extraction using prefilled cartridge MagNA pure compact Nucleic Acid Isolation Kits I (Roche Diagnostic GmbH). DNA concentration was measured using a Thermo Scientific NanoDrop™ 1000 Spectrophotometer (Thermo Fisher Scientific Wilmington, DE, USA). DNA was stored at −20°C until being used for further analysis.

Genotyping by real-time PCR

The genotyping was performed for the polymorphisms Q705K (rs35829419) and C10X (rs2043211) in the NLRP3 and CARD8 genes, respectively, using DNA samples extracted from blood culture bottles. The analysis was performed by a TaqMan® SNP genotyping assay with 7900HT Fast Real-Time PCR system (Applied Biosystems, Foster City, CA, USA) followed by allelic discrimination to evaluate the frequencies of the different alleles. A volume of
2 μL genomic DNA was amplified in a final 20 μL reaction volume containing 10 μL 2x TaqMan® Genotyping Master Mix (Applied Biosystems), 0.5 μL of 20x TaqMan® SNP Genotyping assays Pre-designed primers and probes. Regarding the TaqMan amplification cycles, a cut-off of <35 cycles was used, and for most samples in the present study, the cycles were below 30, which obviously must be considered as a low number of amplification cycles and should not result in any risk of false assignment.

Ethical considerations
The study was conducted in accordance with the Declaration of Helsinki. The blood samples were anonymized, and the only information given was the year of birth and gender of the patients. Since only anonymized samples were delivered to the researchers; thereby preventing data to be traced back to a certain individual, and since the blood was withdrawn from blood culture bottles and not directly from the patients; thereby causing no extra harm to the patients, the study did not require ethical approval according to paragraph 4 of the Swedish law (2003:460) on Ethical Conduct in Human Research.

Statistical analyses
Hardy–Weinberg equilibrium was calculated in accordance with standard procedures using chi-square analysis ($\chi^2$) [22]. The results were analyzed by SPSS 17.0 software package and Prism 5, GraphPad Software. $\chi^2$-test was performed to compare genotype and allele frequencies, or Fisher’s exact test. Moreover, binary logistic regression was used to calculate Odds ratio (OR) at corresponding 95% confidence interval (95% CI). Two-sided statistical significance value, $P < 0.05$ were considered as significant.

Results
Genotype distribution and allele frequencies of Q705K in the NLRP3 gene and C10X in the CARD8 gene
The classification of the microorganisms found in patients with bacteraemia in the present study is detailed in Table 1. Propionibacterium sp. and Lactobacillus are generally non-invasive bacteria, and thus regarded as non-pathogenic. Therefore, these two samples were excluded from the study. In 15 samples, the identified bacterium was coagulase-negative Staphylococcus sp. (CoNS). Out of these, eight samples were found to be positive for growth of CoNS in two or more out of the four blood culture bottles, run in parallel for each patient, and were thus considered as true bacteraemia cases and included in the study.

The prevalence of C10X polymorphism in the CARD8 gene was significantly higher in patients with bacteraemia compared to healthy controls (allele frequencies: 50.0% vs. 32.9%; $P = 0.004$; Table 2). Patients with bacteraemia were to a significantly greater extent heterozygote carriers of C10X in the CARD8 gene (66.6%) than non-bacteraemia patients (55.3%; $P = 0.01$) or healthy controls (46.1%; $P < 0.0001$), and this difference was also evident when comparing the carriers of homoyzgote polymorphism of C10X in the CARD8 gene (Table 2). Patients with bacteraemia displayed no significant difference in genotype distribution and allele frequency of Q705K in the NLRP3 gene compared to healthy individuals as well as to patients with negative blood cultures (Table 3). The polymorphisms were not found to be in Hardy–Weinberg equilibrium ($P < 0.05$, $\chi^2$) in neither the bacteraemia nor the non-bacteraemia group.

If CoNS samples that were regarded as positive, were excluded, the prevalence of C10X polymorphism in the CARD8 gene was even more significant in patients with bacteraemia compared to healthy controls (allele frequencies: 51.0%, $P < 0.0001$; genotype: 67.3%, $P < 0.0001$ (heterozygote) and 17.3, $P = 0.001$ (homozygote variant)).

Table 1. Distribution of pathogens identified in blood culture bottles of seventy consecutive patients, including the patients included in the study.

| Pathogens                                      | Positive samples | Patients included |
|------------------------------------------------|------------------|-------------------|
| Gram positive infection                        |                  |                   |
| Coagulase-negative staphylococci               | 15               | 8                 |
| Staphylococcus aureus                          | 9                | 9                 |
| Streptococcus pneumonia                       | 10               | 10                |
| Enterococcus faecium                           | 1                | 1                 |
| Propionibacterium sp.                          | 2                | 0                 |
| Streptococcus pyogenes                         | 2                | 2                 |
| Enterococcus faecalis                          | 3                | 3                 |
| Lactobacillus sp.                              | 1                | 0                 |
| Streptococcus agalactiae                       | 1                | 1                 |
| Clostridium ramosum                            | 1                | 1                 |
| Gram negative infection                        |                  |                   |
| Escherichia coli                               | 15               | 15                |
| Klebsiella pneumonia                           | 4                | 4                 |
| Enterobacter cloacae                           | 1                | 1                 |
| Fusobacterium sp.                              | 1                | 1                 |
| Proteus mirabilis                              | 1                | 1                 |
| Klebsiella oxytoca                             | 1                | 1                 |
| Haemophilus influenzae                         | 1                | 1                 |
| Bacteroides vulgatus                           | 1                | 1                 |
| Fungal                                          |                  |                   |
| Candida albicans                                | 1                | 0                 |

1 At least two out of four cultures from a patient needed to signal positive for growth of Coagulase-negative Staphylococcus to be included in the study.

2 Fungi (C. albicans) was excluded from the analysis since the infection occurred only in one patient.

© 2013 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd.
Combined genotype frequencies of Q705K in NLRP3 and C10X in CARD8 genes

The frequency of a combined heterozygous genotype (Q705K for the NLRP3 gene plus C10X for the CARD8) in the healthy controls is 6.4% (Table S1 [21]), implying that approximately five patients with bacteraemia would be to expect in our study. However, only few patients displayed a combined heterozygous genotype (patients with bacteraemia: 1; non-bacteraemia patients: 3; Table S1). Due to this small sample size, no comparison of the presence of combined polymorphisms of Q705K in NLRP3 gene plus C10X in the CARD8 gene could be made between patients with bacteraemia and non-bacteraemia patients, nor compared to healthy individuals. Of note, whereas over 35% of the healthy individuals, as well as of the non-bacteraemia patients, were carriers of combined wild-type CARD8 + NLRP3, only 11.7% of the patients with bacteraemia had this genotype (Table S1). None of the groups (neither patients nor controls) held individuals carrying the combined homozygous variant genotype XX of C10X plus KK of Q705K.

**Table 2. Genotype and allele frequencies (%) in patients with bacteraemia (n = 60), patients with negative blood cultures (n = 76; non-bacteraemic samples) and healthy controls (n = 1003) for C10X (rs2043211) polymorphism in the CARD8 gene.**

| Genotype frequencies – CARD8 | Bacteraemic samples (%), n = 60 | Non-bacteraemic samples (%), n = 76 | OR (95% CI)a | P-valuea | Healthy controls (%), n = 1003 | OR (95% CI)b | P-valueb |
|-----------------------------|---------------------------------|-------------------------------------|--------------|----------|---------------------------------|--------------|----------|
| CC                          | 10 (16.7)                       | 30 (39.5)                           | 1            |          | 442 (44.1)                      | 1            |          |
| CX                          | 40 (66.6)                       | 42 (55.3)                           | 2.8 (1.2–6.5) | 0.01     | 462 (46.1)                      | 3.8 (1.8–7.7) | <0.0001 |
| XX                          | 10 (16.7)                       | 4 (5.3)                             | 7.5 (1.9–29.2) | 0.004    | 99 (9.9)                        | 4.4 (1.8–11.0) | 0.001   |

| Allele frequencies – CARD8 | Bacteraemic samples (%), n = 120 | Non-bacteraemic samples (%), n = 152 | OR (95% CI)a | P-valuea | Healthy controls (%), n = 2006 | OR (95% CI)b | P-valueb |
|---------------------------|---------------------------------|-------------------------------------|--------------|----------|---------------------------------|--------------|----------|
| C                         | 60 (50.0)                       | 102 (67.1)                          | 1            |          | 1346 (67.1)                     | 1            |          |
| X                         | 60 (50.0)                       | 50 (32.9)                           | 2.0 (1.2–3.3) | 0.004    | 660 (32.9)                      | 2.0 (1.4–2.9) | 0.0001  |

OR, odds ratio; CI, confidence interval.

aAssociation between bacteraemic and non-bacteraemic samples.
bAssociation between bacteraemic samples and healthy controls.

**Combined genotype frequencies of Q705K in NLRP3 and C10X in CARD8 genes**

The frequency of a combined heterozygous genotype (Q705K for the NLRP3 gene plus C10X for the CARD8) in the healthy controls is 6.4% (Table S1 [21]), implying that approximately five patients with bacteraemia would be to expect in our study. However, only few patients displayed a combined heterozygous genotype (patients with bacteraemia: 1; non-bacteraemia patients: 3; Table S1). Due to this small sample size, no comparison of the presence of combined polymorphisms of Q705K in NLRP3 gene plus C10X in the CARD8 gene could be made between patients with bacteraemia and non-bacteraemia patients, nor compared to healthy individuals. Of note, whereas over 35% of the healthy individuals, as well as of the non-bacteraemia patients, were carriers of combined wild-type CARD8 + NLRP3, only 11.7% of the patients with bacteraemia had this genotype (Table S1). None of the groups (neither patients nor controls) held individuals carrying the combined homozygous variant genotype XX of C10X plus KK of Q705K.

**Table 3. Genotype and allele frequencies (%) in patients with bacteraemia (n = 60), patients with negative blood cultures (n = 76; non-bacteraemic samples) and healthy controls (n = 1003) for Q705K (rs35829419) polymorphism in the NLRP3 gene.**

| Genotype frequencies – NLRP3 | Bacteraemic samples (%), n = 60 | Non-bacteraemic samples (%), n = 76 | OR (95% CI)a | P-valuea | Healthy controls (%), n = 1003 | OR (95% CI)b | P-valueb |
|-----------------------------|---------------------------------|-------------------------------------|--------------|----------|---------------------------------|--------------|----------|
| QQ                         | 54 (90.0)                       | 68 (89.5)                           | 1            |          | 862 (85.9)                      | 1            |          |
| QK                         | 4 (6.7)                         | 6 (7.9)                             | 0.8 (0.2–3.1) | 0.79     | 138 (13.8)                      | 0.5 (0.2–1.2) | 0.14    |
| KK                         | 2 (3.3)                         | 2 (2.6)                             | 1.3 (0.2–9.2) | 0.72     | 3 (0.3)                        | 10.6 (1.7–65) | 0.01   |

| Allele frequencies – NLRP3 | Bacteraemic samples (%), n = 120 | Non-bacteraemic samples (%), n = 152 | OR (95% CI)a | P-valuea | Healthy controls (%), n = 2006 | OR (95% CI)b | P-valueb |
|---------------------------|---------------------------------|-------------------------------------|--------------|----------|---------------------------------|--------------|----------|
| Q                          | 112 (93.3)                      | 142 (93.4)                          | 1            |          | 1862 (92.8)                     | 1            |          |
| K                          | 8 (6.7)                         | 10 (6.6)                            | 1.0 (0.4–2.7) | 0.97     | 144 (7.2)                       | 0.9 (0.4–1.9) | 0.83   |

OR, odds ratio; CI, confidence interval.

aAssociation between bacteraemic and non-bacteraemic samples.
bAssociation between bacteraemic samples and healthy controls.
Table 4. Comparison of genotype frequencies (%) of C10X polymorphism (CARD8 gene) in bacteraemic patients infected with Gram-positive G\(^+\); n = 35) and Gram-negative (G\(^-\); n = 25) bacteria to healthy controls (n = 1003).

| Genotype frequencies – CARD8 | G\(^+\) samples (n = 35) | Healthy controls (n = 1003) | OR (95% CI)\(^a\) | P-value\(^a\) | G\(^-\) samples (n = 25) | OR (95% CI)\(^b\) | P-value\(^b\) |
|-----------------------------|--------------------------|-----------------------------|--------------------|--------------|--------------------------|--------------------|--------------|
| CC                          | 7 (20)                   | 442 (44.1)                  | 1                  |              | 3 (12)                   | 7.4 (1.7–31.7)     | 0.007        |
| CX                          | 23 (65.7)                | 462 (46.1)                  | 3.1 (1.3–7.4)      | 0.009        | 17 (68)                  | 5.4 (1.6–18.6)     |              |
| XX                          | 5 (14.3)                 | 99 (9.9)                    | 3.2 (1.0–10.3)     | 0.052        | 5 (20)                   | 7.4 (1.7–31.7)     |              |

| Allele frequencies – CARD8 | G\(^+\) samples (n = 70) | Healthy controls (n = 2006) | OR (95% CI)\(^a\) | P-value\(^a\) | G\(^-\) samples (n = 50) | OR (95% CI)\(^b\) | P-value\(^b\) |
|----------------------------|--------------------------|-----------------------------|--------------------|--------------|--------------------------|--------------------|--------------|
| C                          | 37 (52.9)                | 1346 (67.1)                 | 1                  |              | 23 (46)                  | 2.4 (1.4–4.2)      | 0.002        |
| X                          | 33 (47.1)                | 660 (32.9)                  | 1.8 (1.1–2.9)      | 0.013        | 27 (54)                  |                   |              |

OR, odds ratio; CI, confidence interval.

\(^a\)Association between G\(^+\) samples (patients with Gram-positive bacteria infection) and Healthy controls.

\(^b\)Association between G\(^-\) samples (patients with Gram-negative bacteria infection) and Healthy controls.

that the few carriers (n = 5) of homozygote variant XX of CARD8 were not associated with infections caused by Gram-positive bacteria (P = 0.052). In addition, the prevalence of C10X polymorphism in CARD8 gene was significantly higher in patients with bacteraemia caused by either Gram-negative bacteria (P = 0.008), or Gram-positive bacteria (P = 0.041) compared to patients with negative culture (Table 5).

**Discussion**

The present study was designed as a case-control study in order to find out if genetic variations of the NLRP3 inflammasome are associated with susceptibility to severe infectious disease. The presence of polymorphisms Q705K (rs35829419) in NLRP3 and C10X (rs2043211) in CARD8 genes were investigated in patients with bacteraemia and compared to severely ill patients without detected bacteraemia, as well as to healthy individuals. The polymorphism C10X in the CARD8 gene was significantly more prevalent in patients with bacteraemia compared to healthy individuals (P < 0.0001). The finding that the C10X polymorphism was not in Hardy–Weinberg equilibrium in the bacteraemic patients (P = 0.0018, \(\chi^2\)) makes the genotype difference between patients with bacteraemia and healthy controls even more evident. The polymorphism C10X causes a nonsense allele; resulting in reduced expression of CARD8 [11, 23], which in turn is suggested to result in a loss of its inhibitory effect on caspase-1, and in so doing, caspase-1 is more easy to trigger. Miller and co-worker [11] speculated that C10X-

Table 5. Comparison of genotype frequencies (%) of C10X polymorphism (CARD8 gene) in bacteraemic patients infected with Gram-positive (G\(^+\); n = 35) and Gram-negative (G\(^-\); n = 25) bacteria to patients with negative blood culture bottles (non-bacteraemic patients; n = 76).

| Genotype frequencies – CARD8 | G\(^+\) samples (n = 35) | Non-bacteraemic samples (n = 76) | OR (95% CI)\(^a\) | P-value\(^a\) | G\(^-\) samples (n = 25) | OR (95% CI)\(^b\) | P-value\(^b\) |
|-----------------------------|--------------------------|-----------------------------|--------------------|--------------|--------------------------|--------------------|--------------|
| CC                          | 7 (20)                   | 30 (39.5)                  | 1                  |              | 3 (12)                   | 7.4 (1.7–31.7)     | 0.007        |
| CX                          | 23 (65.7)                | 42 (55.3)                  | 2.3 (0.9–6.2)      | 0.084        | 17 (68)                  | 4.0 (1.1–15.1)     | 0.037        |
| XX                          | 5 (14.3)                 | 4 (5.3)                    | 5.4 (1.1–25.3)     | 0.034        | 5 (20)                   | 12.5 (2.1–73.5)    | 0.005        |

| Allele frequencies – CARD8 | G\(^+\) samples (n = 70) | Non-bacteraemic samples (n = 152) | OR (95% CI)\(^a\) | P-value\(^a\) | G\(^-\) samples (n = 50) | OR (95% CI)\(^b\) | P-value\(^b\) |
|----------------------------|--------------------------|-----------------------------|--------------------|--------------|--------------------------|--------------------|--------------|
| C                          | 37 (52.9)                | 102 (67.1)                  | 1                  |              | 23 (46)                  | 2.4 (1.2–4.6)      | 0.008        |
| X                          | 33 (47.1)                | 50 (32.9)                  | 1.8 (1.02–3.2)     | 0.041        | 27 (54)                  |                   |              |

OR, odds ratio; CI, confidence interval.

\(^a\)Association between G\(^+\) samples (patients with Gram-positive bacteria infection) and non-bacteremic patients.

\(^b\)Association between G\(^-\) samples (patients with Gram-negative bacteria infection) and non-bacteremic patients.
carriers thereby have a more robust inflammatory response, and thus, better survive under conditions with higher infectious-disease burden, but could, on the other hand, manifest a pronounced inflammation during the acute phase of a severe infection. Our data most strongly support this idea by showing higher prevalence of C10X polymorphism in patients with bacteraemia; in whom septic symptoms may arise as a rapid consequence of an excessive caspase-1 response. In fact, judging from our data, homozygote carrier ship results in a phenotype more susceptible to infectious disease compared to heterozygote carriers; indicating that healthy C10X individuals (especially homozygote C10X) have a higher risk of severe bacteraemia in the case of infectious disease. In support of our finding, blocking caspase-1 decreases inflammation and mortality in rat models of endotoxin-induced shock [24, 25]. Also, caspase-1 deficient mice are sheltered from disease of excessive inflammation, such as bacterial-induced sepsis [26], and are markedly resistant to the lethal effects of endotoxin [27]. These data, taken together with our finding of a high prevalence of wild-type CARD8 allele in the healthy population, suggest that a functional CARD8, which thus controls caspase-1 activity, might provide a better protection against excessive, uncontrolled inflammation. However, the present study does not provide a mechanistic understanding of how the genetic variant C10X acts to alter disease susceptibility. Beside its role in maturation of IL-1 family cytokines, caspase-1 is known to process a number of other proteins [28]; which of many are proteins known to regulate the immune response, as well as to induce pyroptosis; a cell death that influence bacterial clearance independent of IL-1β and IL-18 [29]. Contradictory to our findings, several studies have shown that caspase-1-deficient mice are more susceptible to a number of pathogens [30–32]. Therefore, future studies are needed to understand how C10X modulate the function of the inflammasome in regulating host resistance mechanisms and by that the susceptibility to develop an infection.

CoNS are bacteria that constitute a major part of the normal flora, thus regarded as commensals, and could therefore be considered as a false positive result due to contamination when recovered in blood culture bottles. Since the patients in this study were anonymized, it is not possible to find out whether they represent true bacteraemia cases (e.g. immune-compromised patients, patients with indwelling devices or foreign bodies) or contaminations. Therefore, the most obvious cases of contamination, that is growth of CoNS in one out of four blood culture bottles were excluded, whereas growth of CoNS in two or more bottles were considered as true bacteraemia cases and thus included in the study. Whether CoNS are to be included in the study or not could be argued but if all CoNS samples are withdrawn from the calculations, the prevalence of C10X polymorphism in the CARD8 gene is even more significant in patients with bacteraemia compared to healthy controls; data that argue that including the CoNS does, if anything, impair our results.

Most interestingly, our data show that patients with negative blood culture, that is patients that exhibit severe diseases without detectable bacteraemia, displayed similar expression of C10X as healthy individuals. It has been found that mRNA levels of caspase-1 are affected in patients with microbe-induced septic shock during the first 24 h of disease compared to critically ill intensive care unit patients [4]. This means that the cause of disease (in this case: infectious vs. non-infectious) are of crucial importance to understand the inflammatory response behind the disease, and most certainly therefore also in the treatment of disease. A need to establish the aetiology is most evident in a condition like sepsis, which manifest with similar clinical features even if presented from an infectious or non-infectious background. By separating patients with bacteraemia from non-bacteraemia patients, our study showed a strong correlation between the prevalence of genetic variation of CARD8 and blood stream infection. This finding is supported by data showing only a weak association ($P = 0.050$) between the C10X-genotype and systemic inflammatory response syndrome (SIRS) when infectious and non-infectious SIRS patients were grouped and analyzed together [11]. Even if some caution should be taken into account when interpreting our results since the C10X polymorphism was not in Hardy–Weinberg equilibrium in the non-bacteraemic patients ($P = 0.03, \chi^2$); our data highlights the importance of investigating distinct groups of patients of well-defined aetiologies. Also, these data seem to indicate a contribution of C10X not only to bacteraemia but also the general clinical presentation of sepsis independent of the presence of blood-born infections. In addition, we found that patients carrying C10X are sensitive to infections caused by both Gram-positive and Gram-negative bacteria. Further investigations are needed to find out if all bacteria are causative in this genetic setting.

The C10X-genotype has been found associated with chronic consequences on human health by resulting in severity of autoimmune and auto-inflammatory disease [18, 33, 34]; probably due to a long-term effect of excessive caspase-1 response. We and others have found the combined polymorphism of C10X in CARD8 and Q705K in NLRP3 to be associated with inflammatory diseases [12, 13] and with susceptibility to and severity of rheumatoid arthritis and Crohn’s disease [16, 17, 19]. In this pilot study, only few patients were combined carriers of Q705K + C10X, and, therefore, no analysis of an association of a combined heterozygote Q705K + C10X genotype in patients with bacteraemia could be made. Larger cohorts are needed to investigate whether or not bacteraemia is associated with the combined Q705K + C10X genotype.
In conclusion, the present study showed a strong correlation between C10X polymorphism of the CARD8 gene and the presence of bacteraemia. The current study was not designed to investigate whether C10X also correlates with disease outcome, that is survival or death, or solely to susceptibility of severe infectious disease, and future studies are therefore warranted elucidating this important question. Also, forthcoming studies should by ex vivo experiments validate the association between the gene variant and clinical course, and elucidate the molecular and cellular mechanisms by which the genetic variant C10X alters disease susceptibility.

Acknowledgments

The study was supported by grants from the Swedish Research Council (K2010-57X-21435-01-3), the Swedish Society of Medicine, the Research committee of the County Council of Örebro and Nyckelfonden at Örebro University Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author contributions

All authors contributed to drafting of the paper and revising it critically for intellectual content, and all authors approved of the final version to be published. The corresponding authors had full access to data in the study and take responsibility for integrity of the data and accuracy of data analysis.

Asfaw Idosa, Sahdo, Kelly, Söderquist, and Särndahl conceptualized and designed the study. Särndahl was responsible for coordinating the study. Asfaw Idosa, Sahdo, and Balcha were responsible for performed the experiments. Asfaw Idosa, Sahdo, Balcha, Kelly, Söderquist, and Särndahl were analyzed the data. Kelly, Söderquist, and Särndahl were contributed reagents, materials and analysis tools. Asfaw Idosa, Sahdo, Kelly, Söderquist, and Särndahl wrote the manuscript. Balcha was contributed to the writing of the paper.

Disclosures

B. Söderquist has been a consultant for Pfizer and Janssen-Cilag.

Conflict of Interest

None declared.

References

1. Horvath, G. L., J. E. Schrum, C. M. De Nardo, and E. Latz. 2011. Intracellular sensing of microbes and danger signals by the inflammasomes. Immunol. Rev. 243(1):119–135.
2. Dinarello, C. A. 2011. A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur. J. Immunol. 41(5):1203–1217.
3. Van der Poll, T., and S. M. Opal. 2008. Host-pathogen interactions in sepsis. Lancet Infect Dis. 8(1):32–43.
4. Fahy, R. J., M. C. Exline, M. A. Gavrilin, N. Y. Bhatt, B. Y. Besecker, A. Sarkar, J. L. Hollyfield, M. D. Duncan, H. N. Nagaraja, N. L. Knatz, et al., 2008. Inflammasome mRNA expression in human monocytes during early septic shock. Am. J. Respir. Crit. Care Med. 77(9):983–988.
5. Scott, A. M., and M. Saleh. 2007. The inflammatory caspases: guardians against infections and sepsis. Cell Death Differ. 14(1):23–31.
6. Cinel, I., and S. M. Opal. 2009. Molecular biology of inflammation and sepsis: a primer. Crit. Care Med. 37(1):291–304.
7. Giamarellos-Bourboulis, E. J., F. L. van de Veerdonk, M. Mouktaroudi, M. Raftogiannis, A. Antonopoulou, L. A. B. Joosten, P. Pickkers, A. Sawa, M. Georgitsi, J. W. Van Meer, et al. 2011. Inhibition of caspase-1 activation in Gram-negative sepsis and experimental endotoxemia. Crit. Care. 15(1):R27.
8. Bouchier-Hayes, L., H. Conroy, H. Egan, C. Adrain, E. M. Creagh, M. MacFarlane, S. J. Martin, et al. 2001. CARDINAL, a novel caspase recruitment domain protein, is an inhibitor of multiple NF-kappa B activation pathways. J. Biol. Chem. 276(47):44069–44077.
9. Razmara, M., S. M. Srinivasula, L. Wang, J.-L. Poyet, B. J. Geddes, P. S. DiStefano, J. Bertin, E. S. Alnemri. 2002. CARD-8 protein, a new CARD family member that regulates caspase-1 activation and apoptosis. J. Biol. Chem. 277(16):13952–13958.
10. Pathan, N. H. Marusawa, M. Krajewska, S. Matsuzawa, H. Kim, K. Okada, S. Torii, S. Kitada, S. Krajewski, K. Welsh, et al. 2001. TUCAN, an antiapoptotic caspase-associated recruitment domain family protein overexpressed in cancer. J. Biol. Chem. 276(34):32220–32229.
11. Ko, D. C., K. P. Shukla, C. Fong, M. Wasnick, M. J. Brittnacher, M. M. Wurfel, T. D. Holden, P. E. O’Keefe, B. Van Yserloo, J. M. Akey, et al., 2008. Inflammasome mRNA interactions in sepsis. Lancet. 77(9):983–988.
12. Verma, D., M. Lerm, R. Blomgran Julinder, P. Ericsson, P. Söderkvist, and E. Särndahl. 2008. Gene polymorphisms in the NALP3 inflammasome are associated with interleukin-1 production and severe inflammation: relation to common inflammatory diseases? Arthritis Rheum. 58(1):23–31.
13. Blomgran, R., V. Patcha Brodin D. Verma, I. Bergström, P. Söderkvist, C. Sjöwall, P. Ericsson, M. Lerm, O. Stendahl, and E. Särndahl. 2012. Common genetic variations in the NALP3 inflammasome are associated with delayed apoptosis of human neutrophils. PLoS ONE. 7(3):e31326.
14. Pontillo, A., L. Brandao, R. Guimaraes, L. Segat, J. Araujo, and S. Crovella. 2010. Two SNPs in NLRP3 gene are involved in
p.C10X is associated with bacteraemia

B. Asfaw Idosa et al.

20

© 2013 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd.

the predisposition to type-1 diabetes and celiac disease in a pediatric population from northeast Brazil. Autoimmunity. 43(8):583–589.

15. Pontillo, A., A. Vendramin, E. Catamo, A. Fabris, and S. Crovella. 2011. The missense variation Q705K in CIAS1/NALP3/NLRP3 gene and an NLRP1 haplotype are associated with celiac disease. Am. J. Gastroenterol. 106(3):539–544.

16. Roberts, R. L., R. K. G. Topless, A. J. Pipps-Green, R. B. Geary, M. L. Barclay, and T. R. Merriman. 2010. Evidence of interaction of CARD8 rs2043211 with NALP3 rs35829419 in Crohn’s disease. Genes Immun. 11(4):351–356.

17. Schoultz, I., D. Verma, J. Halfvarsson, L. Töre, M. Fredriksson, U. Sjögqvist, M. Lördal, C. Tysk, M. Lerm, P. Söderkvist, et al. 2009. Combined polymorphisms in genes encoding the inflammasome components NALP3 and CARD8 confer susceptibility to Crohn’s disease in Swedish men. Am. J. Gastroenterol. 104(5):1180–1188.

18. Kastbom, A., M. Johansson, D. Verma, P. Söderkvist, and B. Rantapää-Dahlqvist. 2010. CARD8 p.C10X polymorphism is associated with inflammatory activity in early rheumatoid arthritis. Ann. Rheum. Dis. 69(4):723–726.

19. Kastbom, A., D. Verma, P. Eriksson, T. Skogh, G. Wingren, and P. Söderkvist. 2008. Genetic variation in proteins of the cryopyrin inflammasome influences susceptibility and severity of rheumatoid arthritis (the Swedish TIRA project). Rheumatology (Oxford). 47(4):415–417.

20. Verma, D., E. Särndahl, H. Andersson, P. Eriksson, M. Fredriksson, J.-I. Jönsson, M. Lerm, and P. Söderkvist. 2012. The Q705K polymorphism in NLRP3 is a gain-of-function alteration leading to excessive interleukin-1β and IL-1β production. PLoS ONE. 7(4):e34977.

21. Sahbo, D., K. Fransén, B. Asfaw Idosa P. Eriksson, B. Söderquists, A. Kelly, and E. Söderquist. 2013. Cytokine profile in a cohort of healthy blood donors carrying polymorphisms in genes encoding the NLRP3 inflammasome. PLoS ONE. 8 (10):e75457.

22. Rodríguez, S., T. R. Gaunt, and I. N. M. Day. 2009. Hardy–Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am. J. Epidemiol. 169(4):505–514.

23. Paramel, G. V., L. Folkerstra, R. J. Strawbridge, A. A. Elmbouts, E. Särndahl, P. Lundman, J. H. Jansson, G. K. Hansson, A. Sirsjo, and K. Fransén. 2013. CARD8 gene encoding a protein of innate immunity is expressed in human atherosclerosis and associated with markers of inflammation. Clin. Sci. 125(8):401–407.

24. Mathiak, G., G. Grass, T. Herzheimer, T. Luecke, C. C. Zetina, S. A. Boehm, G. Bohlen, L. F. Neville, and A. H. Hoelscher. 2000. Caspase-1-inhibitor ac-YVAD-cmk reduces LPS-lethality in rats without affecting haematology or cytokine responses. Br. J. Pharmacol. 131(3):383–386.

25. Boost, K. A., S. Hoegl, C. Hofstetter, M. Flondor, K. Stegewerth, I. Platacis, J. Pleischfier, H. Muhl, and B. Zwissler. 2007. Targeting caspase-1 by inhibition-therapy: effects of Ac-YVAD-CHO on IL-1 beta, IL-18 and downstream proinflammatory parameters as detected in rat endotoxemia. Intensive Care Med. 33(5):863–871.

26. Sarkar, A., M. W. Hall, M. Exline, J. Hart, N. Knatz, N. T. Gatzon, and M. D. Wevers. 2006. Caspase-1 regulates Escherichia coli sepsis and splenic B cell apoptosis independently of interleukin-1beta and interleukin-18. Am. J. Respir. Crit. Care Med. 174(9):1003–1010.

27. Li, P. H. Allen, S. Banerjee, S. Franklin, L. Herzog, C. Johnston, J. McDowell, M. Paskind, L. Rodman, J. Salfeld, et al. 1995. Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell. 80(3):401–411.

28. Agard, N. J., D. Maltby, and J. A. Wells. 2010. Inflammatory stimuli regulate caspase substrate profiles. Mol Cell Proteomics. 9(5):880–893.

29. Miao, E. A., I. A. Leaf, P. M. Treuting, D. P. Mao, M. Dors, A. Sarkar, S. E. Warren, M. D. Wevers, and A. Aderem. 2010. Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nat. Immunol. 11(12):1136–1142.

30. Tsuji, N. M., H. Tsutsui, E. Seki, K. Kuida, H. Okamura, K. Nakamiji, and R. A. Flavell. 2004. Roles of caspase-1 in Listeria infection in mice. Int. Immunol. 16(2):335–343.

31. Lara-Tejero, M., F. S. Sutterwala, Y. Ogura, E. P. Grant, J. Bertin, A. J. Coyle, R. A. Flavell, and J. E. Galán. 2006. Role of the caspase-1 inflammasome in Salmonella typhimurium pathogenesis. J. Exp. Med. 203(6):1407–1412.

32. Mariathasan, S., D. S. Weiss, V. M. Dixa, and D. M. Monack. 2005. Innate immunity against Francisella tularensis is dependent on the ASC/caspase-1 axis. J. Exp. Med. 202(8):1043–1049.

33. Fontalba, A., O. Gutierrez, J. Llorca, I. Mateo, J. Berciano, J. L. Fernandez-Luna, and O. Combarros. 2008. Deficiency of CARD8 is associated with increased Alzheimer’s disease risk in women. Dement Geriatr. Cogn. Disord. 26(3):247–250.

34. Fontalba, A., V. Martinez-Taboada, O. Gutierrez, C. Pipason, N. Benito, A. Balsa, R. Blanco, and J. L. Fernandez-Luna. 2007. Deficiency of the NF-kappaB inhibitor caspase activating and recruitment domain 8 patients with rheumatoid arthritis is associated with disease severity. J. Immunol. 179(7):4867–4873.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of this article at the publisher’s web-site.

Table S1. Combined genotype frequencies (%) of the polymorphism C10X (rs2043211) in the CARD8 gene and Q705K (rs35829419) in the NLRP3 gene in patients with bacteraemia (n = 60), patients with negative blood cultures (n = 76; non-bacteraemic samples) and healthy controls (n = 1003).